Steward Partners Investment Advisory LLC Invests $1.37 Million in Becton Dickinson and Co (BDX) Stock

Steward Partners Investment Advisory LLC acquired a new stake in Becton Dickinson and Co (NYSE:BDX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,970 shares of the medical instruments supplier’s stock, valued at approximately $1,365,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Westwood Holdings Group Inc. increased its holdings in shares of Becton Dickinson and by 24.2% during the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock worth $206,136,000 after buying an additional 205,721 shares during the last quarter. Colony Group LLC increased its holdings in shares of Becton Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock worth $2,320,000 after buying an additional 239 shares during the last quarter. State Street Corp increased its holdings in shares of Becton Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after buying an additional 342,873 shares during the last quarter. Peapack Gladstone Financial Corp increased its holdings in shares of Becton Dickinson and by 1.3% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock worth $7,116,000 after buying an additional 453 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Becton Dickinson and by 35.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after buying an additional 11,300 shares during the last quarter. Institutional investors and hedge funds own 88.60% of the company’s stock.

Shares of Becton Dickinson and Co (NYSE BDX) opened at $221.46 on Friday. Becton Dickinson and Co has a 1-year low of $161.50 and a 1-year high of $229.68. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The firm has a market cap of $49,874.81, a P/E ratio of 23.05, a P/E/G ratio of 1.71 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter last year, the company posted $2.12 EPS. The firm’s revenue was down 2.0% compared to the same quarter last year. equities analysts expect that Becton Dickinson and Co will post 10.63 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.35%. The ex-dividend date is Thursday, December 7th. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio (DPR) is currently 64.52%.

BDX has been the subject of several research reports. Argus lifted their target price on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday. They noted that the move was a valuation call. Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “sector perform” rating and issued a $230.00 target price (up previously from $210.00) on shares of Becton Dickinson and in a report on Friday, November 3rd. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $218.36.

TRADEMARK VIOLATION WARNING: “Steward Partners Investment Advisory LLC Invests $1.37 Million in Becton Dickinson and Co (BDX) Stock” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://sportsperspectives.com/2017/12/16/steward-partners-investment-advisory-llc-invests-1-37-million-in-becton-dickinson-and-co-bdx-stock.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply